Curis is a biotechnology company dedicated to pioneering first-in-class, innovative cancer therapies. With a robust pipeline of differentiated small-molecule drug candidates, Curis is currently focused on advancing emavusertib (CA-4948), an oral IRAK4 kinase inhibitor, for the treatment of non-Hodgkin’s lymphoma and leukemia (AML/MDS).
Curis is a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. We are focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study, both as a monotherapy and in combination with the BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia study (AML and hrMDS)